A Two-part Adaptive Double-blind Randomized Placebo-controlled Study to Assess the Appropriate Dose and the Appropriate Dosing Frequency of ALDP 001 in Adults With Seasonal Allergic Rhinitis (SAR) Assessed Using an Allergen Challenge Chamber/EEC
Latest Information Update: 28 Oct 2025
At a glance
- Drugs Alcaftadine (Primary)
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors Alixer Nexgen Therapeutics
Most Recent Events
- 28 Oct 2025 New trial record